Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis Forms US Subsidiary

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis announced today that it is establishing a US subsidiary in support of its recent distribution deal with Thermo Fisher Scientific.

Under an agreement announced in November, Biocartis' real-time PCR-based Idylla platform and assays will be distributed in the US by Thermo Fisher Scientific, with an initial focus on the oncology market. Biocartis retains the right to sell the products via direct sales channels.

With the commercial rollout of its products in the US expected to begin mid-year, Biocartis said that it has set up the new subsidiary — called Biocartis US — under the direction of newly appointed general manager of US operations Vishal Sikri.

"With a broad background varying from clinical trial management to sales and marketing, medical affairs, business development, and M&A, and a particular expertise in liquid biopsy testing and companion diagnostics, we are confident that Vishal will successfully establish Biocartis in one of the largest molecular diagnostics markets in the world," Biocartis CEO Hilde Windels said in a statement.

The US office will open in the New Jersey area, Biocartis said.